Skip to content

Study for the effect of acupuncture intervention on the patients with amnestic mild cognitive impairment based on the theory of "brain-kidney correlation"

Study for the effect of acupuncture intervention on the patients with amnestic mild cognitive impairment based on the theory of "brain-kidney correlation"

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400084932
Enrollment
Unknown
Registered
2024-05-28
Start date
2024-06-30
Completion date
Unknown
Last updated
2024-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

amnestic mild cognitive impairment

Interventions

Acupuncture group:Acupuncture at Shenting, Baihui, Sanyinjiao, Taixi, Dazhong
Sham acupuncture group:Sham acupuncture at 8 non-acupoints

Sponsors

Chengdu University of Traditional Chinese Medicine; Affiliated hospital of Chengdu University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients who meet 8 following criteria will be included: (1) diagnosis of aMCI according to the Jak/Bondi 2014 diagnostic criteria; (2) fifty to eighty years of age, without limitation of sex; (3) course of disease=3 months; (4) the Clinical Dementia Rating (CDR) score is 0.5; (5) the Hachinski Incheinic Score (HIS)=4; (6) education years=8 (including vocational education) and correct understanding the completion of scales; (7) volunteering to cooperate and sign an informed consent form; (8) no contraindications to magnetic resonance imaging (MRI) scanning.

Exclusion criteria

Exclusion criteria: Patients will be excluded if they meet any of the following criteria: (1) receiving treatment that interferes with cognitive function (e.g., the treatment of acute psychotic illness, such as memantine, rivastigmine, donepezil, oxiracetam, and sodium oligomannate capsules); (2) a history of neurological conditions affecting cognitive function confirmed by examination, except in patients with suspected early AD (including Parkinson's disease, vascular dementia, brain tumour, traumatic brain injury, or other diseases which might lead to neurological injury and abnormal brain structure). Presence of a systemic diseases that could cause cognitive decline (such as anaemia, Hashimoto's encephalopathy, metabolic encephalopathy, hepatic encephalopathy, and renal encephalopathy); (3) the brain MRI showing infection or other local lesions, infarction in vital memory brain areas, multiple embolic infarctions, or severe white matter lesions (Fazekas score=3); (4) a history of tumour, psychiatric illness (e.g., bipolar disorder, schizophrenia), or severe anxiety (Hamilton anxiety [HAMA] scale score=29), major epression (Hamilton Depression [HAMD] scale score=24); (5) severe haemorrhagic disease, bleeding tendency, or skin infection; (6) severe drug dependence, smoking, drug, or alcohol abus ; (7) pregnant, lactating females, or potentially pregnant; (8) receipt of any acupuncture treatment or participation in other clinical trials within 6 months before enrollment.

Design outcomes

Primary

MeasureTime frame
Alzheimer's Disease Assessment Scale - Cognitive;

Secondary

MeasureTime frame
Word recall and word recognition score of Alzheimer's Disease Assessment Scale - Cognitive;Hamilton Anxiety Scale;Hamilton Depression Scale;Pittsburgh Sleep Quality Index;

Countries

China

Contacts

Public ContactFanrong Liang

Chengdu University of Traditional Chinese Medicine; Affiliated hospital of Chengdu University of Traditional Chinese Medicine

acuresearch@126.com+86 136 0805 8216

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 22, 2026